Last reviewed · How we verify
NDV-3 investigational vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
NDV-3 investigational vaccine (NDV-3 investigational vaccine) — NovaDigm Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NDV-3 investigational vaccine TARGET | NDV-3 investigational vaccine | NovaDigm Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NDV-3 investigational vaccine CI watch — RSS
- NDV-3 investigational vaccine CI watch — Atom
- NDV-3 investigational vaccine CI watch — JSON
- NDV-3 investigational vaccine alone — RSS
Cite this brief
Drug Landscape (2026). NDV-3 investigational vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/ndv-3-investigational-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab